NASDAQ:KRBP

Kiromic BioPharma (KRBP) Stock Forecast, Price & News

$2.85

-0.15 (-5.00%)

(As of 02:18 PM ET)

Compare

Today's Range: $2.80
▼
$3.15
50-Day Range: $2.86
▼
$5.22
52-Week Range: $2.59
▼
$22.80

Volume: 124,154 shs
Average Volume: 246,203 shs
Market Capitalization: $2.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Kiromic BioPharma (NASDAQ:KRBP) Stock

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

KRBP Stock News Headlines

May 18, 2023 | americanbankingnews.com

Critical Analysis: Kiromic BioPharma (NASDAQ:KRBP) and Cullinan Oncology (NASDAQ:CGEM)

May 14, 2023 | americanbankingnews.com

Short Interest in Kiromic BioPharma, Inc. (NASDAQ:KRBP) Declines By 46.5%

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 3, 2023 | finance.yahoo.com

What's Going On With Kiromic BioPharma Stock Wednesday

May 1, 2023 | finance.yahoo.com

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

May 1, 2023 | americanbankingnews.com

Kiromic BioPharma, Inc. (NASDAQ:KRBP) Short Interest Up 7.5% in April

April 3, 2023 | finance.yahoo.com

Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer

March 10, 2023 | finance.yahoo.com

Kiromic BioPharma Announces Reverse Stock Split

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

February 28, 2023 | finance.yahoo.com

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results

February 23, 2023 | finance.yahoo.com

Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote "FOR" All Proxy Proposals

February 16, 2023 | msn.com

Kiromic BioPharma CEO encourages stock split, sees Deltacel trial in 2Q23

February 16, 2023 | finance.yahoo.com

Kiromic BioPharma CEO Issues Letter to Stockholders

January 15, 2023 | yahoo.com

Cambrian BioPharma Unveils New Pipeline Company - Isterian Biotech

January 15, 2023 | seekingalpha.com

CTI BioPharma: Checking Back In

October 27, 2022 | finance.yahoo.com

Kiromic BioPharma Arranges Up to $10 Million Financing

October 14, 2022 | finance.yahoo.com

Kiromic Shares Surge After Streamlining Operations To Execute Deltacel-Aligned Development Strategy

October 6, 2022 | finance.yahoo.com

Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

October 6, 2022 | marketwatch.com

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class Action

October 5, 2022 | stockhouse.com

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

October 5, 2022 | theglobeandmail.com

Kiromic BioPharma: Top 10 Undervalued Healthcare Stocks on NAS (KRBP)

October 4, 2022 | benzinga.com

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

October 4, 2022 | benzinga.com

Hagens Berman, National Trial Attorneys, Announces It Has Filed A Class Action Lawsuit Against Kiromic BioPharma (KRBP)

October 3, 2022 | benzinga.com

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate

October 2, 2022 | prnewswire.com

KRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit

October 1, 2022 | benzinga.com

Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Kiromic BioPharma, Inc. (KRBP) Investors of Filing Deadline in Class Action Lawsuit

September 24, 2022 | prnewswire.com

KRBP DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important October 4, 2022 Deadline Reminder for Kiromic BioPharma, Inc.

See More Headlines

KRBP Price History

30 days | 90 days | 365 days | Advanced Chart

KRBP Company Calendar

Today: 6/02/2023
Next Earnings (Estimated): 6/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KRBP
CUSIP: N/A
CIK: 1792581
Web: www.kiromic.com
Phone: 832-968-4888
Fax: N/A
Employees: 19
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($30.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -475.16%
Return on Assets: -202.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.18
Quick Ratio: 0.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($8.31) per share
Price / Book: -0.36

Miscellaneous

Outstanding Shares: 980,000
Free Float: 907,000
Market Cap: $2.94 million
Optionable: Not Optionable
Beta: 0.17

Key Executives

Mr. Pietro Bersani CPA (Age 55)
J.D., CEO & Director
Comp: $167.76k

Dr. Scott Dahlbeck M.D. (Age 61)
Pharm.D., PharmD, Chief of Staff
Comp: $442.12k

Mr. Daniel Clark (Age 34)
Chief Financial Officer

Dr. Leonardo Mirandola Ph.D.
Chief Scientific Officer

Dr. Michael Ryan Ph.D. (Age 56)
Chief Bioinformatics Research Computing Officer

Key Competitors

View All Competitors

Institutional Ownership

Susquehanna International Group LLP
Bought 16,457 shares on 5/16/2023
Ownership: 1.681%

View All Institutional Transactions

KRBP Stock - Frequently Asked Questions

How have KRBP shares performed in 2023?: Kiromic BioPharma's stock was trading at $5.4210 at the start of the year. Since then, KRBP stock has decreased by 44.7% and is now trading at $3.00.
View the best growth stocks for 2023 here.
When is Kiromic BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, June 2nd 2023.
View our KRBP earnings forecast.
When did Kiromic BioPharma's stock split?: Shares of Kiromic BioPharma reverse split before market open on Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
When did Kiromic BioPharma IPO?: (KRBP) raised $16 million in an IPO on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager.

What is Kiromic BioPharma's stock symbol?: Kiromic BioPharma trades on the NASDAQ under the ticker symbol "KRBP."
Who are Kiromic BioPharma's major shareholders?: Kiromic BioPharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Susquehanna International Group LLP (1.68%). Insiders that own company stock include Internati Maurizio Chiriva and Jerry A Schneider.
View institutional ownership trends.
How do I buy shares of Kiromic BioPharma?: Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kiromic BioPharma's stock price today?: One share of KRBP stock can currently be purchased for approximately $3.00.
How much money does Kiromic BioPharma make?: Kiromic BioPharma (NASDAQ:KRBP) has a market capitalization of $2.94 million. The company earns $-34,730,000.00 in net income (profit) each year or ($30.33) on an earnings per share basis.
How can I contact Kiromic BioPharma?: The official website for the company is www.kiromic.com. The company can be reached via phone at 832-968-4888 or via email at bus.dev@kiromic.com.

This page (NASDAQ:KRBP) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial